Spyre Therapeutics Reports Positive Six-Month Phase 1 Data for Anti-TL1A Antibody SPY072 in Rheumatic Diseases

Reuters

10/24

<a href="https://laohu8.com/S/SYRE">Spyre Therapeutics</a> Reports Positive Six-Month Phase 1 Data for Anti-TL1A Antibody SPY072 in Rheumatic Diseases

Spyre Therapeutics Inc. announced new scientific presentations at the upcoming American College of Rheumatology $(ACR)$ Convergence Congress. The company will present follow-up data from its Phase 1 study of SPY072, an investigational anti-TL1A monoclonal antibody being developed for rheumatic diseases. Interim results indicate that SPY072 is well tolerated and exhibits a pharmacokinetic profile that may support maintenance dosing every three or six months. In addition, new preclinical data will be presented showing that anti-TL1A antibody treatment demonstrated efficacy comparable to or exceeding etanercept in a rodent model of collagen-induced arthritis. These data provide further support for the ongoing SKYWAY Phase 2 study evaluating SPY072 in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis. The posters will be available for viewing during the ACR Convergence Congress.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spyre Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9550156-en) on October 24, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2577137245"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2577137245\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2577137245?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-24 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2577137245","market":"fut","top_or_hot":-1,"title":"Spyre Therapeutics Reports Positive Six-Month Phase 1 Data for Anti-TL1A Antibody SPY072 in Rheumatic Diseases","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/SYRE\">Spyre Therapeutics</a> Reports Positive Six-Month Phase 1 Data for Anti-TL1A Antibody SPY072 in Rheumatic Diseases\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Spyre <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. announced new scientific presentations at the upcoming American College of Rheumatology <a href=\"https://laohu8.com/S/ACR\">$(ACR)$</a> Convergence Congress. The company will present follow-up data from its Phase 1 study of SPY072, an investigational anti-TL1A monoclonal antibody being developed for rheumatic diseases. Interim results indicate that SPY072 is well tolerated and exhibits a pharmacokinetic profile that may support maintenance dosing every three or six months. In addition, new preclinical data will be presented showing that anti-TL1A antibody treatment demonstrated efficacy comparable to or exceeding etanercept in a rodent model of collagen-induced arthritis. These data provide further support for the ongoing SKYWAY Phase 2 study evaluating SPY072 in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis. The posters will be available for viewing during the ACR Convergence Congress.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spyre Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9550156-en) on October 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Spyre Therapeutics Reports Positive Six-Month Phase 1 Data for Anti-TL1A Antibody SPY072 in Rheumatic Diseases</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSpyre Therapeutics Reports Positive Six-Month Phase 1 Data for Anti-TL1A Antibody SPY072 in Rheumatic Diseases\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-10-24 20:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/SYRE\">Spyre Therapeutics</a> Reports Positive Six-Month Phase 1 Data for Anti-TL1A Antibody SPY072 in Rheumatic Diseases\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Spyre <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. announced new scientific presentations at the upcoming American College of Rheumatology <a href=\"https://laohu8.com/S/ACR\">$(ACR)$</a> Convergence Congress. The company will present follow-up data from its Phase 1 study of SPY072, an investigational anti-TL1A monoclonal antibody being developed for rheumatic diseases. Interim results indicate that SPY072 is well tolerated and exhibits a pharmacokinetic profile that may support maintenance dosing every three or six months. In addition, new preclinical data will be presented showing that anti-TL1A antibody treatment demonstrated efficacy comparable to or exceeding etanercept in a rodent model of collagen-induced arthritis. These data provide further support for the ongoing SKYWAY Phase 2 study evaluating SPY072 in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis. The posters will be available for viewing during the ACR Convergence Congress.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spyre Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9550156-en) on October 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251024:nNDLmMH4j:1","article_id":"2577137245","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2577137245","pubTimestamp":1761307226,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Spyre Therapeutics Inc. announced new scientific presentations at the upcoming American College of Rheumatology  Convergence Congress. The company will present follow-up data from its Phase 1 study of SPY072, an investigational anti-TL1A monoclonal antibody being developed for rheumatic diseases. Interim results indicate that SPY072 is well tolerated and exhibits a pharmacokinetic profile that may support maintenance dosing every three or six months. In addition, new preclinical data will be presented showing that anti-TL1A antibody treatment demonstrated efficacy comparable to or exceeding etanercept in a rodent model of collagen-induced arthritis. These data provide further support for the ongoing SKYWAY Phase 2 study evaluating SPY072 in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis. The posters will be available for viewing during the ACR Convergence Congress.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelli","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","SYRE":"SPYRE THERAPEUTICS INC"},"translate_title":"Spyre Therapeutics报告抗TL1A抗体SPY072治疗风湿性疾病的6个月1期阳性数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SYRE":0.9},"content_text":"Spyre Therapeutics Reports Positive Six-Month Phase 1 Data for Anti-TL1A Antibody SPY072 in Rheumatic Diseases\n    \n\n        Spyre Therapeutics Inc. announced new scientific presentations at the upcoming American College of Rheumatology $(ACR)$ Convergence Congress. The company will present follow-up data from its Phase 1 study of SPY072, an investigational anti-TL1A monoclonal antibody being developed for rheumatic diseases. Interim results indicate that SPY072 is well tolerated and exhibits a pharmacokinetic profile that may support maintenance dosing every three or six months. In addition, new preclinical data will be presented showing that anti-TL1A antibody treatment demonstrated efficacy comparable to or exceeding etanercept in a rodent model of collagen-induced arthritis. These data provide further support for the ongoing SKYWAY Phase 2 study evaluating SPY072 in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis. The posters will be available for viewing during the ACR Convergence Congress.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spyre Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9550156-en) on October 24, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}